ARCHIVES

FDA examining endpoints for approval of cancer therapies, potential departure from survival as the gold standard, Oncology Division Director Richard Pazdur says in interview.

This article is from The Cancer Letter archive.

Vol. 29 No. 41 | November 7, 2003

Download PDF Visit The Full Archive

Related Articles

Poll Finds Strong Support For Research; Yarbro Leads International Cancer Nurses.

October 6, 2000

FDA Advisors Ok Marketing Of Taxotere As Treatment For Advanced Breast Cancer

October 20, 1995

Fogarty Leads Grant Program On World Tobacco Research.

July 6, 2001

NCAB Approves Plan for Public Participation Hearings Around U.S.

February 20, 1987

Trials Suspended At Oklahoma Over Study Of Cancer Vaccine.

July 14, 2000

DCBDC Advisors Ok Training Grant Program In Clinical Oncology

February 22, 1991